TICKERNERD
Menu
TLSITLSIHealthcare · Medical Devices

TLSI Stock Forecast: TriSalus Life Sciences, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$5.27
+0.76% on the day

The 4 Wall Street analysts covering TriSalus Life Sciences, Inc. hold a median 12-month price target of $9.5 — +80.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 29 of 100 as at 22 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$324.5M
Ticker Nerd rank
29 / 100
Median analyst target
$9.50
Analysts covering
4
Total return, dividends reinvested
1W
0.0%
1M
+21.4%
YTD
−24.5%
1Y
+6.3%
From 52W high
−29.7%
From 52W low
+109.1%
$2.52
$7.50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TLSI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TriSalus Life Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
29 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
65
Size
61
Revisions
48
Momentum
43
Quality
42
Growth
38
Value
37
Volatility
34
Issuance
14

Accruals (65): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (14): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TLSI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TLSI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Oct 25Jan 26Apr 26Jul 26TLSIHigh $14.00Median $9.50Low $7.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $7.00Median $9.50High $14.00

The green dot is the last close — the median target sits +80.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
13 May 2026Lake StreetMaintainsBuy$10 → $8.00
9 Mar 2026Canaccord GenuityMaintainsBuy—
6 Mar 2026Canaccord GenuityMaintainsBuy—
17 Dec 2025Canaccord GenuityMaintainsBuy—
28 Mar 2025Canaccord GenuityMaintainsBuy—
13 Feb 2025Lake StreetInitiatesBuy—
24 Jan 2025Roth MKMReiteratesBuy—
17 Dec 2024Cantor FitzgeraldInitiatesOverweight—
15 Nov 2024Canaccord GenuityMaintainsBuy—
11 Nov 2024Roth MKMInitiatesBuy—
25 Oct 2024Northland Capital MarketsInitiatesOutperform—
16 Sept 2024OppenheimerInitiatesOutperform—
27 June 2024Canaccord GenuityMaintainsBuy—
30 May 2024Canaccord GenuityInitiatesBuy—
10 May 2024JonesTradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TLSI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TLSI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

TriSalus Life Sciences, Inc. (TLSI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
7.2×

Cheaper than 18% of US stocks

Price / book
49.3×

Cheaper than 2% of US stocks

EV / EBITDA
−10.4×

Cheaper than 84% of US stocks

Growth & margins
Revenue growth (YoY)
1.7%

Higher than 31% of US stocks

Earnings growth (YoY)
1.7%

Higher than 38% of US stocks

Gross margin
86.8%

Higher than 95% of US stocks

Operating margin
−86.0%

Higher than 14% of US stocks

Net margin
−62.6%

Higher than 9% of US stocks

Returns & dividend
Return on equity
205.8%

Higher than 98% of US stocks

Return on assets
−36.8%

Higher than 11% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TLSI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices
CompanyMarket capTKN rank
TLSITriSalus Life Sciences, Inc.$324.5M
29
RCELAVITA Medical, Inc.$306.8M
63
ELMDElectromed, Inc.$329.0M
99
CVCapsoVision, Inc.$300.0M
20
VMDViemed Healthcare, Inc.$336.5M
96
MOBIMobia Medical, Inc.$351.0M
2
TMCITreace Medical Concepts, Inc.$276.5M
55

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TriSalus Life Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TLSI news & analysis

TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference

MarketBeat · 18 Aug 2026neutral

TriSalus Life Sciences presented at Canaccord Genuity's Global Growth Conference, outlining its commercial expansion, product pipeline, and clinical-evidence strategy. Management emphasized the company's pressure-enabled delivery technology for solid-tumor treatments.

Why it matters — TLSI watchers would value insight into the company's commercial strategy, pipeline progress, and the clinical evidence behind its pressure-enabled delivery technology for solid tumors.

TriSalus Life Sciences Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026positive

TriSalus Life Sciences reported second-quarter revenue of $11.4 million, up 1.7% from $11.2 million a year earlier, citing increased demand for its TriNav pressure-enabled drug delivery system. The company reiterated its full-year 2026 revenue outlook of $54 million to $57 million, representing projected growth of 19% to 26% over 2025.

Why it matters — The year-over-year revenue growth and reaffirmed full-year outlook point to ongoing demand for TriSalus' TriNav system, giving investors an updated view of the company's near-term performance.

TriSalus Life Sciences, Inc. (TLSI) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

Seeking Alpha published the transcript of TriSalus Life Sciences, Inc.'s (TLSI) Q2 2026 earnings call. The item is an announcement of the transcript's availability rather than a report on the call's content.

Why it matters — A TLSI watcher would find the transcript useful for reviewing management's discussion of the company's second-quarter 2026 results and outlook.

TriSalus Life Sciences Reports Second Quarter 2026 Results

Business Wire · 6 Aug 2026positive

TriSalus Life Sciences, Inc. (TLSI) announced financial results for the quarter ended June 30, 2026, and provided an operational update, noting second-quarter year-over-year growth and strong sequential growth.

Why it matters — The report gives TLSI watchers an update on the company's quarterly financial performance and operational progress for its oncology treatments.

TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference

Business Wire · 29 July 2026neutral

TriSalus Life Sciences announced that CEO Mary Szela and CFO David Patience will participate in the Canaccord Genuity 46th Annual Growth Conference, including one-on-one meetings.

Why it matters — Conference participation gives management a platform to present the company's strategy and engage directly with investors, which can influence market sentiment and visibility.

FAQ

Frequently asked questions about TLSI stock

What is the TLSI stock price forecast for 2026-2027?

The 4 Wall Street analysts covering TriSalus Life Sciences, Inc. have a median 12-month price target of $9.5, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TLSI stock a buy right now?

Of the 4 analysts covering TriSalus Life Sciences, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks TriSalus Life Sciences, Inc. 29 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TLSI?

As at 22 Aug 2026, TriSalus Life Sciences, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (65 of 100).

Will TLSI stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +80.3% from the last close, and Ticker Nerd's factor model ranks TriSalus Life Sciences, Inc. 29 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TLSI stock forecast for 2030?

No analyst covering TriSalus Life Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TLSI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.

How has TLSI stock performed over the past year?

TriSalus Life Sciences, Inc. returned +6.3% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TriSalus Life Sciences, Inc. do?

TriSalus Life Sciences Inc. operates as a biopharmaceutical company focused on the development of innovative therapies in the treatment of cancer.

What is the latest news on TLSI?

The most recent item we track (MarketBeat, 18 Aug 2026): "TriSalus Highlights Tumor-Treatment Expansion, FDA Catalyst at Growth Conference". TriSalus Life Sciences presented at Canaccord Genuity's Global Growth Conference, outlining its commercial expansion, product pipeline, and clinical-evidence strategy. Management emphasized the company's pressure-enabled delivery technology for solid-tumor treatments.

Company

About TriSalus Life Sciences, Inc.

TriSalus Life Sciences Inc. operates as a biopharmaceutical company focused on the development of innovative therapies in the treatment of cancer. The company primarily targets solid tumors, utilizing unique delivery technologies to improve the effectiveness and distribution of immunotherapies directly within tumors. By addressing issues related to vascular perfusion and immune suppression in tumor environments, TriSalus seeks to enhance outcomes for patients undergoing difficult cancer treatments. Notable in its portfolio is the company's proprietary Pressure-Enabled Drug Delivery (PEDD) technology, which plays a crucial role in facilitating better drug penetration and distribution. TriSalus Life Sciences actively collaborates with research institutions and healthcare providers to bring cutting-edge treatment options from clinical trials to commercial availability. Positioned within the biotechnology industry, the company's work significantly impacts oncological therapeutic strategies, offering potential advancements in cancer treatment modalities. Through its dedicated approach, TriSalus Life Sciences Inc. contributes to the broader life sciences market, aspiring to transform cancer care.

CEO Ms. Mary T. Szela B.S.N., M.B.A. · 102 employees · United States · https://trisaluslifesci.com